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Abstract
Streptococcus pneumoniae causes different types of acute, invasive and non-invasive clinical infections, being the most frequently detected
pathogen responsible for community-acquired pneumonia. Pneumococcal pneumonia is accompanied by bacteraemia in 10–30% of cases.
Streptococcus pneumoniae is gaining resistance to the in vitro activity of several antimicrobial agents and, even if questions remain regard-
ing the clinical impact of this phenomenon, more and more reports indicate that antibiotic resistance can lead to more treatment fail-
ures if not higher mortality. Use of the 23-valent anti-pneumococcal vaccine appears to offer subpotimal protection against
pneumococcal disease, particularly among high-risk adult populations. Vaccination against S. pneumoniae with new conjugate vaccines
seems to be the most promising field for real improvement in the management of pneumococcal infections in adults.
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Introduction
Streptococcus pneumoniae is one of the most important causes
of morbidity and mortality worldwide, being the first aetio-
logical pathogen of pneumonia [1,2]. Streptococcus pneumoniae
is part of the commensal flora of the upper respiratory tract
and colonizes the nasopharyngeal niche. Colonization seems
to be an important feature because pneumococcal disease
will not occur without the preceding nasopharyngeal coloni-
zation [3]. The clinical spectrum of pneumococcal infection
ranges from acute otitis media and sinusitis to pneumonia.
When the organism invades normally sterile sites such as the
bloodstream and meninges, the resulting forms of pneumo-
coccal disease are classified as invasive.
In nature, S. pneumoniae is present in at least 92 different
serotypes. The serotypes differ greatly in nasopharyngeal car-
riage prevalence, invasiveness and disease incidence. The vast
majority of the burden of pneumococcal disease is associated
with a rather restricted number of serotypes. The most
commonly encountered are serotypes 3 (16.9%), 19 (10.7%)
and 14 (7.5%). Serotypes have different pathogenicities. Sero-
type 2 frequently causes invasive disease, Serotypes 3, 4, 6A,
6B, 7, 9N, 9V, 11, 12, 14, 15A, 15F, 16, 18C, 22, 23A, 23B,
31, 33 and 35 are associated with mortality [4,5].
Epidemiology and clinical burden
Most of the burden of pneumococcal infections in adults is in
fact related to pneumonia. Community-acquired pneumonia
(CAP) is a major respiratory health disease with high preva-
lence in the general population, clinical heterogeneity and
variable severity. Both in the USA and in Europe, CAP is the
most frequent cause of death from infection and has implica-
tions for healthcare systems worldwide [6–8]. The reported
incidence of CAP varies considerably from country to coun-
try and study to study, but reports are consistent in identify-
ing a progression in rate with increasing patient age [9].
Given that in Europe the population mean age is sharply
increasing, it is to be expected that over the next decades
an important increase of pneumonia hospital admissions and
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costs will take place [10]. Altered immune competence is an
additional risk factor for pneumonia, with evidence of human
immunodeficiency virus (HIV)-infected subjects presenting a
25-fold increase in bacterial pneumonia compared with the
general population [11].
Infection with influenza virus increases the risk of develop-
ing S. pneumoniae pneumonia and pneumococcal invasive dis-
ease [12,13]. It has been estimated that secondary
pneumococcal infections may have caused as much as 20%
mortality during the 1918–19 influenza pandemic, as demon-
strated in a review of autopsy series, which found that 27%
of blood cultures were positive for S. pneumoniae [14]. A
study conducted during the 2009 H1N1 pandemic found a
significant increase in pneumococcal hospitalizations at the
time of highest pandemic influenza activity [15]. Individuals
aged 5–19 years, who have low baseline levels of pneumo-
coccal disease, experienced the largest relative increase in
pneumococcal hospitalizations (ratio 1.6; 95% CI 1.4–1.7),
whereas the largest absolute increase was observed among
individuals aged 40–64 years. In contrast, there was no
excess disease in the elderly.
A recent review tried to define the burden of CAP among
adults in Europe [16]. Forty-six primary articles were analy-
sed and S. pneumoniae was reported as the most frequently
isolated pathogen, being isolated in 38% of outpatient cases,
27% of inpatient cases, and 28% of intensive-care pneumonia
cases. Among the different European countries, pneumococcal
identification rates were lowest in Italy (11.9%), and highest in
Finland (68.3%) [16]. Worldwide pneumococcal pneumonia
morbidity and mortality rates are still remarkable. The mor-
tality rate ranges from 6.4% to >40% in the different setting of
outpatients, inpatients and intensive-care patients [17].
Increasing age is also a risk factor for pneumonia mortality.
Pneumococcal pneumonia is accompanied by bacteraemia
in 10–30% of cases and it is then classified as invasive. The
incidence of invasive pneumococcal disease is affected by a
number of factors, including, smoking status, immune status,
age and geographical location. Reported incidence rates of
invasive pneumococcal disease (IPD) in European and US
studies indicate an overall incidence between 11 and 23.2
per 100 000 population, which rises to 16.2–59.7/100 000
population in adults aged over 65 years [18–21]. These stud-
ies were conducted between 1995 and 2003, before wide-
spread use of pneumococcal conjugate vaccine in children,
which has been associated with a ‘herd immunity’ effect caus-
ing decreased IPD incidence in unvaccinated adults (see later)
[22,23]. In subjects with chronic medical conditions IPD inci-
dence rises further to 176–483/100 000 [20], and reaches
342–2031/100 000 population among immunosuppressed
patients [20,24]. Even when appropriate antibiotic treatment
is instituted, IPD mortality remains high, involving 10–25% of
patients [25].
Economic impact of pneumococcal disease
The White Book edited by the European Respiratory Society
estimated that the annual financial burden of pneumonia in
the 51 countries of the WHO Europe region is higher than
€10 billion, with inpatient care accounting for around €6 bil-
lion annually. Pneumonia accounts for >30% of hospital days
in respiratory units and loss of work days generate indirect
costs of more than €3.5 billion [26]. The median direct costs
of treating patients hospitalized with CAP in Germany were
$1333 per case [8]. Major contributors to the total direct
costs were expenses for staff and bed occupancy. In an Ital-
ian investigation on the costs of respiratory diseases, the
average cost/year for treating a single CAP patient was esti-
mated to be €1586.04 [27]. A study conducted in Spain cal-
culated the mean direct costs for CAP management as €196
for outpatients and €1553 for inpatients [28]. In many of
these economic-based studies microbiological work up was
not rigorously standardized and cost associations for specific
pathogens are therefore difficult. Nonetheless, considering
that S. pneumoniae is thought to cause 30–50% of CAP cases,
it may be assumed that a sizable portion of these costs may
be attributable to pneumococcal disease.
One recent study specifically investigated the economic
burden of pneumococcal disease [29]. This was a cost analy-
sis performed in the USA using a model combining age-spe-
cific and risk-group-specific data on rates and costs of
disease. The authors found that the annual clinical and eco-
nomic burden of pneumococcal disease among US adults
aged over 50 years was about $3.7 billion in total direct
costs, and $1.8 billion in total indirect costs.
Antibiotic resistance
The existence of antibiotic-resistant S. pneumoniae strains is
a well-known phenomenon across most countries world-
wide. Despite escalation in antimicrobial resistance rates
worldwide over the past decades [30], mortality rates for
IPD (including pneumonia and bacteraemias) have not
increased [31]. Treatment failures because of drug-resistant
strains have been reported but a causative role has not been
convincingly established. Drug resistance is a microbiological
laboratory finding and the exact impact of this ‘in vitro’ phe-
nomenon on treatment outcomes in clinical practice is still
debatable.
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Two different systematic reviews and meta-analyses of the
available data on the implications of S. pneumoniae penicillin
resistance on outcome reach different conclusions. Metlay
[4] evaluated 15 studies involving over 7500 patients with
pneumococcal pneumonia. Twelve of the fifteen studies anal-
ysed by the authors failed to demonstrate any relationship
between antibiotic resistance and mortality. Conversely, Tle-
yjeh et al. [32] systematically reviewed ten prospective
cohort studies involving >3400 patients, and observed a
19.4% mortality rate among penicillin-non-susceptible S. pneu-
moniae infections as opposed to 15.7% among penicillin-sus-
ceptible pneumococcal infections. In this review, the
combined adjusted relative risk of short-term mortality for
penicillin-non-susceptible vs. susceptible pneumococcus was
1.29 (95% CI 1.04–1.59).
In interpreting these studies it must be kept in mind that
mortality associated with pneumococcal infection is influ-
enced by a number of clinical factors independent of antimi-
crobial susceptibility, such as host factors (e.g. age,
immunosuppression, comorbidities), and virulence factors
(e.g. capsular subtype). These issues are not easily accounted
for in clinical studies, and may bias attempts to correlate
decreased antibiotic susceptibility with outcome parameters.
In addition, systematic reviews and meta-analyses are most
informative when based on randomized controlled clinical
trials. However, in this setting, because of logistical and ethi-
cal considerations, all the analysed studies are observational,
albeit prospective in design, introducing concerns regarding
quality assessment.
Macrolide resistance in S. pneumoniae may have greater
clinical importance than penicillin resistance. Epidemiological
data show a striking increase in pneumococcal resistance
rates to macrolides worldwide. Reports from Germany, USA
and other European and Asian countries showed a resistance
rate that varies from 18% to 75% [33–35]. Most of the pub-
lished studies did not show any increase of mortality related
to macrolide non-susceptibility, but several studies showed
an increased rate of failures and possible breakthrough bac-
teraemia during macrolide treatment of macrolide-resistant
pneumococcal pneumonia [36–39].
Failure of first-line empirical therapy leads to an increase
of costs related to longer hospital stay and the use of sec-
ond-line antibiotics [33]. In fact, a study conducted in the Ve-
neto Region in Italy showed that the cost of second-line
antibiotics after initial failure accounted for €1342 per patient
[40].
To contain the emergence and spread of drug-resistant
pneumococcal strains, judicious use of antimicrobials has
been suggested to avoid a selective advantage for these anti-
microbial-resistant organisms. Given that six serotypes (i.e.
6A, 6B, 9V, 14, 19F, 23F) account for >80% of penicillin-
resistant or macrolide-resistant S. pneumoniae strains world-
wide [41], use of vaccines providing activity towards the
above strains may also prove a valuable tool in curbing fur-
ther increases in resistance rates.
Clinical impact of vaccines on
pneumococcal infections
Development of an effective anti-pneumococcal vaccine has
been a slow process, mainly because of the poor immunoge-
nicity of bacterial surface polysaccharides, which are the pri-
mary target of opsonizing antibodies. In the early 1980s, a
vaccine containing purified capsular polysaccharides from 23
of the known pneumococcal serotypes (PPV23) (see Table 1)
was marketed in the USA, and later in Europe. The sero-
types involved are responsible for 85–90% of IPD cases
among adults [42]. Polysaccharides are T-cell-independent
antigens that generally stimulate short-lived B-cell responses
by driving the differentiation of B cells to plasma cells to
produce antibodies [43]. New memory B cells are not pro-
duced in response to most polysaccharide vaccines. Follow-
ing a single dose of PPV23, serotype-specific IgG, IgA and
IgM are produced, with the IgG2 subclass dominating the IgG
response. Responses are age-dependent and serotype-depen-
dent. Antibody responses to vaccination are generally lower
in elderly persons than in younger adults. As a result of the
T-cell-independent immunological response, there is no
anamnestic or booster response on revaccination [43].
Given the considerable burden of morbidity and mortality
associated with pneumococcal disease, several observational
studies and randomized controlled trials (RCTs) have been
conducted to evaluate polysaccharide vaccine efficacy as a
preventing agent. The fact that the impressive number of 17
meta-analyses, the last of which was published in 2009 [44],
have reviewed these trials between 1994 and 2009 testifies
that there are many areas of uncertainty regarding true
vaccine efficacy. The most commonly evaluated and clinically
relevant outcome measures include IPD, all-cause pneumo-
nia, pneumococcal pneumonia and mortality (all-cause or
TABLE 1. Serotypes covered by main polysaccharide and
conjugate pneumococcal vaccines
Vaccine Included serotypes
PPV23 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14,
15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F
PCV7 4, 6B, 9V, 14, 18C, 19F, 23F
PCV10 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 23F
PCV13 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F
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pneumonia-related). All-cause pneumonia rates are often
used as a surrogate marker for pneumococcal pneumonia
given the low yield of diagnostic tests for definitive identifica-
tion of S. pneumoniae as the aetiological agent.
All told, there seems to be little doubt regarding the pro-
tective action of the polysaccharide vaccine against IPD in
healthy adults and, to a lesser extent, among elderly individu-
als. For example, the 2008 Cochrane review [45] analysed
15 RCTs (involving >48 000 participants) and included seven
observational studies (involving >62 000 subjects) that pro-
vided adjustment for important confounding factors. Meta-
analysis of the RCTs found that the polysaccharide vaccine
reduced the risk of IPD with an OR of 0.26 (95% CI 0.15–
0.46). This correlated with a protective vaccine efficacy of
74% (95% CI 56–85%). The protective effect does not seem
to apply to patient subgroups because it was absent in adults
with chronic illness, a vulnerable population for pneumococ-
cal disease. Meta-analysis of the seven non-RCTs showed
vaccine protective efficacy towards IPD of 52% (95% CI 37–
61%), which was maintained in the subgroup of elderly
immunocompetent patients.
Polysaccharide vaccine efficacy against other outcomes
such as pneumonia or mortality is less clear. In the Cochrane
2008 meta-analysis [45], efficacy against all-cause pneumonia
among RCTs gave an OR of 0.71 (95% CI 0.52–0.97), which
was judged as inconclusive because of substantial heteroge-
neity among the included studies. Likewise, the study failed
to demonstrate evidence for polysaccharide vaccination
effectiveness against all-cause mortality. The most recently
published meta-analysis in the field is noteworthy in that data
were analysed according to the methodological quality of the
trials [44]. Once again, the authors found no apparent effi-
cacy of polysaccharide vaccines for presumptive pneumococ-
cal pneumonia, all-cause pneumonia or mortality. One
observational study that reported some benefit in preventing
pneumococcal pneumonia found that best efficacy was regis-
tered in healthy adults, but PPV23 failed to protect the
elderly and populations at risk such as patients with chronic
illness and immune suppression [46]. The latest RCT using
PPV23 was conducted among 1006 elderly nursing home res-
idents (mean age 85 years) in Japan [47]. The authors found
a protective vaccine efficacy of 44.85% (95% CI 22.4–60.8,
p <0.0006) against all-cause pneumonia and a vaccine efficacy
of 63.8% (95% CI 32.1–80.7, p <0.0015) against pneumococ-
cal pneumonia. The study has been criticized for methodo-
logical reasons [48]. In the study, significantly more
participants with pneumococcal pneumonia died in the pla-
cebo group than in the vaccine group: 35.1% (13/37) vs. 0%
(0/14) (p <0.01). However, this did not translate into a
reduction in all-cause mortality in the overall population
(vaccine group 89/502 (17.7%) vs. placebo group 80/504
(15.9%), p 0.4), notwithstanding pneumonia accounted for
32.5% of deaths in the control group.
The results of the above-reported meta-analyses have
been quoted to indicate PPV23 efficacy/lack of efficacy on
different clinical outcomes. However, PPV23 was actually
used in a limited number of the evaluated studies (7/22 stud-
ies included in the 2008 Cochrane review [45], and 8/22
included in the 2009 meta-analysis [44]). The remaining stud-
ies considered vaccine valencies ranging from 2 to 17 sero-
types, with a preference for the 14-valent vaccine. This must
be kept under consideration when interpreting results on
PPV23 efficacy.
At present, there is little evidence that PPV23 protects
against pneumococcal infections in the high-risk group of
adults with HIV. Robust studies of PPV23 in HIV-infected
persons are lacking [49]. Inefficacy of the vaccine in this
group of patients could be attributed to the impaired pro-
duction of capsule-specific IgG during the course of HIV
infection. The only randomized control trial of PPV23 effi-
cacy in HIV-infected patients showed potentially harmful out-
comes in a Ugandan population [50]. However, this study
and most others in the field were undertaken at a time when
the availability of highly active antiretroviral therapy was not
widespread, making results difficult to evaluate in the current
context of care.
Attempts have been made to evaluate the cost-effective-
ness of PPV23 vaccination of high-risk groups. In most stud-
ies evidence was found that PPV23 is relatively cost-effective
and is particularly cost-saving when given to specific popula-
tions at high risk for pneumococcal disease such as the
elderly. One such study determined the cost-effectiveness of
pneumococcal vaccination of persons aged >65 years in pre-
venting hospital admission for both invasive pneumococcal
disease and pneumococcal pneumonia in five western Euro-
pean countries. Assuming a common incidence (50 cases per
100 000) and mortality rate (20–40%) for invasive disease,
the cost-effectiveness ratios were <12 000 ecu (European
currency units) per quality-adjusted life-year in all five coun-
tries [51]. It must be kept in mind that most studies on the
topic were conducted before widespread pneumococcal con-
jugate vaccination among children. Given the beneficial ‘herd
immunity’ effects observed in non-vaccinated adults (see
later), the cost-effectiveness of PPV23 should probably be
reassessed.
Following vaccination with PPV23, pneumococcal sero-
type-specific IgG antibody titres decrease considerably by
5 years [52]. Given that the incidence of pneumococcal dis-
ease increases dramatically with age, revaccination of ageing
patients is an attractive preventive strategy. However,
10 Clinical Microbiology and Infection, Volume 18 Supplement 5, October 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 5), 7–14
routine revaccination is not recommended because of con-
cerns regarding potential immunological hyporesponsiveness
with subsequent vaccine doses. Hyporesponsiveness is a phe-
nomenon whereby the first dose of PPV23 may blunt the
immune response to subsequent doses. This may be brought
about by circulating antibodies derived from the first dose
binding to vaccine antigen from the second dose, so prevent-
ing presentation to B cells [53], through induction of mem-
ory suppressor T cells [54], or depletion of memory B cells
after polysaccharide vaccination [55]. Although a second vac-
cination with PPV23 may generate lower antibodies com-
pared with those generated by the first vaccination, it is
difficult to judge whether this translates into a meaningful
decrease in magnitude of clinical protection.
The above limitations and doubts regarding PPV23 efficacy
in populations most vulnerable to pneumococcal disease has
stimulated investigation using alternative vaccine strategies. In
addition to polysaccharide vaccines, so called ‘conjugate’ vac-
cines are now available. In these conjugate vaccines polysac-
charide antigens are chemically conjugated to a highly
immunogenic protein carrier (such as tetanus or diphtheria
toxoid). From an immunological standpoint, conjugate vac-
cines direct processing of the protein carrier by polysaccha-
ride-specific B cells and presentation of the resulting
peptides to carrier-peptide-specific T cells in association with
MHC class II molecules [43]. Therefore, a conjugate polysac-
charide vaccine induces both a B-cell-dependent and a T-cell-
dependent response and induces an anamnestic (memory)
response to a booster dose of the vaccine [54].
Conjugate vaccines were initially applied to young children
given that polysaccharide vaccines are poorly immunogenic in
this population. A pneumococcal conjugate vaccine contain-
ing capsular polysaccharides from seven serotypes (PCV7)
(see Table 1), designed for children younger than 2 years,
was licensed in the USA in the year 2000. Implementation of
the conjugated vaccine has tremendously decreased invasive
pneumococcal diseases by vaccine serotypes in children [55].
Evidence exists that the elderly have indirectly benefited
from the introduction of the pneumococcal conjugate vac-
cine in children [22,23,56]. For example, in one study, IPD
rates after PCV7 introduction compared with the prevaccina-
tion era were 32% lower for adults aged 20–39 years (7.6
cases/100 000 vs. 11.2/100 000, p <0.001), 8% lower for
those aged 40–64 years (19.7/100 000 vs. 21.5/100 000,
p 0.03), and 18% lower for those aged 65 years or more
(49.5/100 000 vs. 60.1/100 000, p <0.001) [22]. This indirect
effect of vaccination is known as the herd effect or ‘herd
immunity’, defined as the indirect protection of unvaccinated
persons, whereby an increase in the prevalence of vaccine
immunity prevents circulation of infectious agents among
unvaccinated susceptible populations [57]. The herd effect
has had a major impact in the eradication of smallpox [58].
Specifically, because children are the main reservoir of
S. pneumoniae (about 60% carrier rate), reduction in carrier
rate in this population has beneficial effects on pneumococcal
circulation that extend to non-vaccinated adult age groups.
As a result of the reduced disease risk in adults following
introduction of PCV7 among children, the magnitude of the
potential benefit derived from PPV23 in older adults has also
decreased, because of the lower risk of acquiring disease due
to PCV7 strains.
An additional observed benefit following the introduction
of PCV7 was a reduction in the rates of antimicrobial-resis-
tant S. pneumoniae invasive pneumococcal disease. One study
detected a 49% reduction (from 16.4/100 000 pre-PCV7 to
8.4 cases/100 000 post-PCV7) of penicillin-non-susceptible
pneumococcal strains [59]. In a different study, the introduc-
tion of PCV7 reduced the incidence of antibiotic resistance
recorded in 1999 and 2002, from 40.8% to 26.4%, respec-
tively for penicillin, from 34.9% to 9.4% for cephalosporin
and from 29.5% to 18.1% for erythromycin [60].
As a result of these findings there has been interest in
investigating the use of direct immunization of adult popula-
tions with conjugate vaccines. Given the shortcomings of
PPV23 in groups at increased risk for pneumococcal disease
such as the elderly and the immunosuppressed, studies have
mainly involved these specific subpopulations. Possible advan-
tages of conjugate vaccination in adult at-risk populations
include higher protection against vaccine serotypes, and the
possibility of prolonging the duration of protection by
repeated vaccinations over time. Indeed, a trial comparing
PPV23 with standard paediatric dose (0.5 mL) PCV7 in pneu-
mococcal vaccine-naive patients aged >70 years found higher
antibody titres following conjugate vaccine than after polysac-
charide vaccination [61]. In a study on elderly patients who
had previously been vaccinated with PPV23, revaccination
with double-dose (1.0 mL) PCV7 was associated with higher
post-vaccination antibody levels compared with revaccination
with PPV23 [62]. Studies in HIV-infected adults, patients with
chronic obstructive pulmonary disease and adult stem cell
transplant recipients have similarly shown PCV7 to have a
superior immune response compared with PPV23 [63–65].
Although probably more immunogenic than PPV23, PCV7
contains a smaller number of serotypes compared with the
polysaccharide vaccine. One strategy could be to first vacci-
nate susceptible adults with PCV7 and later also offer PPV23.
The rationale is based on PCV7 inducing T-cell memory
responses to the seven serotypes, which would be boosted
by a subsequent dose of PPV23, along with the B-cell
response induced by the polysaccharide vaccine to serotypes
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not included in PCV7. There are concerns that if the order
in which vaccines are administered is reversed, and PPV23 is
administered first, then hyporesponsiveness may limit clinical
efficacy. In the study by Jackson et al. [62], patients who
received PCV7 followed by PPV23 showed an increase in
antibody titres, conversely, in those who initially received
PPV23, subsequent response to PCV7 was blunted.
In the years following the introduction of PCV7 there has
been an increase in the number of cases of IPD caused by
serotypes not covered by the seven-valent pneumococcal
conjugate vaccine, but present in PPV23 (particularly sero-
type 19A, which is associated with antibiotic resistance), and
serotypes not present in either vaccine (such as 23A) [66].
Emergence of non-vaccinal serotypes as a cause of pneumo-
coccal disease may offset the beneficial herd effect. In one
study, although bacteraemic pneumococcal disease in adults
caused by vaccine serotypes decreased by 29% per year, the
rate of disease due to non-vaccine serotypes increased by
13% per year [67]. Therefore, the relative reduction of vac-
cine serotypes appears to be greater than the increase of
non-vaccine serotypes.
New conjugate vaccines are now being evaluated for the
vaccination of children and adults, a ten-valent (PCV10),
which has been licensed in over 30 countries, and a 13-valent
(PCV13) vaccine (see Table 1). The increased serotype cov-
erage of these vaccines, particularly PCV13, may expand the
clinical benefits of conjugate vaccines in adult populations at
risk for pneumococcal disease. A large Dutch randomized
controlled trial designed to test the protective efficacy of
PCV13 towards pneumococcal pneumonia is currently
underway, and will enrol over 85 000 patients aged over
65 years [68]. A simulation study on the cost-effectiveness of
the three conjugate vaccines showed that the introduction of
PCV10 vs. PCV7 reduces by $32 131.51 the cost for quality-
adjusted life-years utility per time and PCV13 vs. PCV10 by
$34 790.19 for quality-adjusted life-years gained, taking into
account both direct and indirect (herd) effects [69]. Some
authors suggest that, given the expected indirect herd
immunity beneficial effects in adult at-risk populations fol-
lowing widespread paediatric newer conjugate vaccine (e.g.
PCV13) immunization, the need for direct vaccination of
adult populations may be diminished [70]. However, fur-
ther data are needed to confirm this hypothesis. A recent
randomized, double blind trial evaluated concomitant
PCV13 and trivalent influenza vaccination in adults aged
‡65 years, and found acceptable immunogenicity and safety
compared with either agent alone. The possibility of
administering both vaccines concomitantly is an important
way to facilitate immunization of high-risk populations
[71].
Lastly, studies are underway for the development of pneu-
mococcal vaccines based on protein components such as
pneumolysin that are antigenically conserved across different
serotypes and may therefore provide protection against
most serotypes [72].
Conclusions
The aging population aging and the epidemic in chronic ill-
ness will lead to a sharp increase of pneumococcal infection
rates and costs. Prevention of pneumococcal infections by
vaccination may be a valid strategy to reduce the burden of
diseases, antibiotics resistance and costs. Vaccination strate-
gies based on the use of more effective vaccines, in particular
the PCV13 vaccine, are expected to have a substantial pub-
lic-health impact on infectious disease and health services
costs, reducing the burden of pneumococcal infection.
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